Mr. Thomas Smeenk reports

HEMOSTEMIX (PRECERV INC.) RETAINS CHRIS MCNORGAN PHD TO LICENSE NCP-01 TO NEURAL ELECTRODE BRAIN IMPLANT COMPANY

Hemostemix Inc. has engaged Dr. Chris McNorgan, PhD, to drive a licence agreement of NCP-01 with a company that is pursuing neural-electrode-based brain intervention. Dr. McNorgan's research -- the neural bases of cognition, including AI (artificial intelligence) methods to decode and simulate neocortical representations of knowledge and motor intention -- is directly relatable to neural-electrode-based implantation.

Dr. McNorgan directed the computational cognitive neuroscience (CCN) laboratory at the University of Buffalo, where he and his research trainees combined functional MRI (magnetic resonance imaging), deep learning and behavioural studies to explore the neural bases of cognition. His research explores how the brain's wiring shapes how we think, primarily in the context of two domains: multisensory semantic processing, which refers to how people think and understand the world with respect to the five senses; and, reading, which is a highly practised skill that maps printed symbols into words that people hear in their heads.

Both activities require co-operation and communication across a network of functionally specialized brain regions, and both can be impacted by damage to the brain or by developmental learning disorders that affect how brain regions communicate.

"Understanding the relationships between brain connectivity and behaviour can improve our models of human cognitive processes and help better understand and treat disorders that arise when this connectivity is disrupted or improved," stated Dr. McNorgan. "NCP offers the recipient its own neuronal cells, which is a great basis to potentially and significantly improve that connectivity. For the most part, neurons do not renew themselves, gradually dying off over the lifetime, either because of disease or the normal aging process. NCP may be an important step towards developing a fountain of youth for the brain, helping it regain the ability to rewire itself," Dr. McNorgan said.

"NCPs are generated from the patient's own blood and are programmed to generate neurons, astrocyte and oligodendrocyte populations in situ as well as releasing into the host milieu neurotrophic factors and cytokines known to inhibit inflammation and cellular destruction (apoptosis). NCP-01 would therefore appear to be an exceptional candidate for supporting implantations of electrodes," stated Dr. Henderson, chief medical officer, a practising neurosurgeon. "We believe the introduction of NCP-01 before, during and after electrode implantation will have a protective effect on the targeted cell population, promoting healing, minimizing complications and enhancing the signalling processes through promotion of synaptogenesis," Dr. Henderson said. "In layman's terms, our prospects will understand that NCP-01 is a leading candidate to support increased neuronal activity at the site of transplantation and, dose dependently, adjunctively within the central and peripheral nervous system," Dr. Henderson said.

"In a preclinical stroke model, NCPs demonstrated homing to the site of stroke and engraftment at the site of stroke. These properties may better facilitate the implantation and acceptance of electrodes," stated Dr. Sarel, chief scientific officer, "especially when we witness NCPs release of brain-derived growth factors, nerve growth factors, glial growth factors and neurotrophins."

"Our team now includes top experts in neural cell precursors, neurosurgery and computational AI-based neuroscience," stated Thomas Smeenk, chief executive officer. "I think Chris's expertise, supported by Dr. Henderson's neurosurgical and Dr. Sarel's stem cell expertise, will drive a licence deal of great interest to our shareholders."

Dr. McNorgan will reach out to and meet with potential partners to discuss licensed applications of NCP-01, alone or in combination with ACP-01, for the neural-electrode-based implantation markets.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed, patented and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors.

We seek Safe Harbor.